Clinical Trial Update: Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

A Phase II trial of CNCT19 cell therapy for relapsed or refractory Non-Hodgkin's lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• CNCT19 (CNCT19 cell therapy)

Snippet

Sponsor: Juventas Cell Therapy Ltd. | Conditions: Non-Hodgkin's Lymphoma | Phase 2 | Status: RECRUITING